Novo Nordisk ( NVO ) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug , amycretin.

Yahoo Finance senior health reporter Anjalee Khemlani breaks down these trial results and the position it gives Novo Nordisk in better competing with Eli Lilly's ( LLY ) newer emerging GLP-1 treatments.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here .

This post was written by Luke Carberry Mogan .